VYNE Therapeutics
VYNE
52 hedge funds and large institutions have $161M invested in VYNE Therapeutics in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 12 closing their positions.
260% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 5
39% more capital invested
Capital invested by funds: $116M → $161M (+$44.7M)
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
8% more funds holding
Funds holding: 48 → 52 (+4)
0.12% more ownership
Funds ownership: 0.86% → 0.99% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.2M |
| 2 |
First Manhattan
New York
|
+$7.86M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.14M |
| 4 |
O
OrbiMed
New York
|
+$4.05M |
| 5 |
JP Morgan Chase
New York
|
+$4.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$10.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.08M |
| 3 |
Millennium Management
New York
|
-$1.74M |
| 4 |
D.E. Shaw & Co
New York
|
-$231K |
| 5 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$200K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
51
Prelude Capital Management
New York
| $1K | -$16.7K | -27 | -96% |
|
52
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
PA
53
Perceptive Advisors
New York
| – | -$10.1M | -17,240 | Closed |
|
|
54
Fidelity Investments
Boston,
Massachusetts
| – | -$9.08M | -15,529 | Closed |
|
|
55
Millennium Management
New York
| – | -$1.74M | -2,973 | Closed |
|
|
56
D.E. Shaw & Co
New York
| – | -$231K | -395 | Closed |
|
|
OAM
57
Oxford Asset Management
Oxford,
United Kingdom
| – | -$131K | -227 | Closed |
|
58
Citadel Advisors
Miami,
Florida
| – | -$130K | -223 | Closed |
|
59
Balyasny Asset Management
Chicago,
Illinois
| – | -$96K | -165 | Closed |
|
|
CWM
60
Cornerstone Wealth Management
St. Peters,
Missouri
| – | -$200K | -23 | Closed |
|
|
TRCT
61
Tower Research Capital (TRC)
New York
| – | -$8K | -13 | Closed |
|
62
UBS Group
Zurich,
Switzerland
| – | -$7K | -11 | Closed |
|
63
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -3 | Closed |
|
|
PIA
64
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$1K | -2 | Closed |
|
VYNE Hedge Fund Activity: Q3 2018 in Review
52 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2018, worth a combined $161M — up 39% from $116M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VYNE positions and 12 closed out — a net gain of 4 holders — while 18 added to existing stakes and 5 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $11.2M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.1M sold.
- 52 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2018, up from 48 in Q2 2018.
- Funds reported $161M of VYNE Therapeutics stock for Q3 2018, up 39% quarter-over-quarter.
- 16 funds opened new VYNE Therapeutics positions in Q3 2018 and 12 closed out, a net change of +4 holders.
- The largest VYNE Therapeutics buyer in Q3 2018 was Great Point Partners, an estimated $11.2M added.
- The largest VYNE Therapeutics seller in Q3 2018 was Perceptive Advisors, an estimated $10.1M sold.
Based on aggregated 13F filings for Q3 2018.